MedTrace Logo

A DDI Study of JMKX000623 and Metformin Hydrochloride

NCT06066060 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-04-25

No results posted yet for this study

Summary

A phase 1, single center, 1 sequence, 3 period, open label, multiple doses study to evaluate the drug-drug interaction of JMKX000623 tablet and metformin.

Conditions

  • Healthy
  • Drug-Drug Interaction

Interventions

DRUG

JMKX000623

JMKX000623, administered orally ;

DRUG

Metformin

Metformin,administered orally

Sponsors & Collaborators

  • Jemincare

    lead INDUSTRY

Principal Investigators

  • Xiaojie Wu, MD · Huashan Hospital

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-17
Primary Completion
2023-11-06
Completion
2023-11-06

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06066060 on ClinicalTrials.gov